Cargando…
Prerequisite of doing clinical trial with drugs in COVID-19 patients: Situational experience
Autores principales: | Thangaraju, Pugazhenthan, Jindal, Atul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513783/ https://www.ncbi.nlm.nih.gov/pubmed/33033705 http://dx.doi.org/10.4103/picr.PICR_184_20 |
Ejemplares similares
-
Be vigilant in treating a patient with diabetes and COVID-19-associated mucormycosis
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2023) -
Does Remdesivir maintain the race in the general treatment protocol of COVID-19?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2021) -
Diligence needed on treatment of primary multidrug-resistant pulmonary tuberculosis with concomitant COVID-19 infection
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2022) -
Vigilance in selection of low-dose versus high-dose steroids in COVID-19
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2021) -
Violence against doctor – few points to be focussed
por: Thangaraju, Pugazhenthan
Publicado: (2020)